Citations

Clear

87 citation(s) found for "Sousa, De".

REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer
Boggi, Ugo , Kauffmann, Emanuele F. , Barreto, Savio George , Fusai, Giuseppe , Hackert, Thilo , Hilal, Mohammad Abu , Shrikhande, Shailesh, Truty, Mark J. , Werner, Jens , Wolfgang, Christopher L. , Capretti, Giovanni , Cattelani, Alice , Sio, Davide De , Dato, Armando Di, Meo, Giovanna Di , Gianfaldoni, Cesare , Salinas, C , Montorsi, Roberto Maria , Pagnanelli, Michele , Poli, Andrea , Sucameli, Francesco , Viti, Virginia, Addeo, Pietro , Bachellier, Philippe , Barbarello, Linda, Busquets, Juli , Butturini, Giovanni , Caniglia, Fabio, Chunhua, Xi, Colangelo, Ettore, Coratti, Andrea , Costa, Francesca, Crafa, Francesco , Valle, Raffaele Dalla , Carlis, Luciano De , Chiaro, Marco Del , Domak, Safi, Ercolani, Giorgio , Filauro, Marco, Gruttaduaria, Salvatore, Izbicki, Jakob R. , Jovine, Elio , Kiguchi, Gozo , Kooby, David A. , Lang, Hauke , Lombardo, Carlo , Massani, Marco , Miao, Yi , Mishima, Kohei , Molino, Carlo , Nardo, Bruno , Panaro, Fabrizio , Pasquali, Claudio , Perrone, Vittorio, Rangelova, Elena , Liu, Rong, Romito, Raffaele, Rosso, Edoardo , Schulick, Richard D. , Spampinato, Marcello , Troisi, Roberto , Uzunoglo, Faik G, Veneroni, Luigi , Zerbi, Alessandro , Vicente, Emilio, Vistoli, Fabio , Wakabayashi, Go , Zanus, Giacomo , Zureikat, Amer H., Zyromski, Nicholas J. , Davide, José , Dervenis, Christos, Konlon, Kevin C., Michelassi, Fabrizio, Nealon, William H. , Portolani, Nazario , Silva, Donzília Sousa , Ferrari, Viviana Nicoleta, Cameron, John L., Clavien, Pierre‐Alain , Asbun, Horacio J. , Board, The REDISCOVER Multidisciplinary Advisory, Truty, Mark, Napoli, Niccolò , Besselink, Marc G , Marchegiani, Giovanni , Salvia, Roberto , Bannone, Elisa , Coppola, Alessandro , Cucchetti, Alessandro , Fiorillo, Claudio , Ginesini, Michael , Lai, Quirino , Miccoli, Mario , Ricci, Claudio , Tamburrino, Domenico , Alfieri, Sergio , Baiocchi, Gian Luca , Balzano, Gianpaolo , Brolese, Alberto , Caputo, Damiano D. , Casadei, Riccardo , Wilde, Roeland F. de , Benedetto, Fabrizio Di , Sebastiano, Pierluigi Di , Hogg, Melissa E. , Egorov, V. , Ettorre, Giuseppe M , Falconi, Massimo , Ferrari, Giovanni , Ferrero, Alessandro , Giardino, Alessandro , Grazi, Gian Luca , Gruttadauria, Salvatore , Katz, Matthew H. G. , Keck, Tobias , Khatkov, Igor , Malleo, Giuseppe , Mazzaferro, Vincenzo , Memeo, Riccardo , Nagakawa, Yuichi , Nakamura, Masafumi , Liu, Rong, Romagnoli, Renato , Siriwardena, Ajith K. , Strobel, Oliver , Testini, Mario , Valente, Umberto , Vivarelli, Marco , Coppola, Roberto , D’Andrea, Vito , Frigerio, Isabella M. , Montorsi, Marco , Bozzi, Giuseppe, Ferrari, Viviana, Trivella, Maria Giovanna , Board, The REDISCOVER Multidisciplinary Advisory

Mayo Clinic

Annals of Surgery | February 26, 2024 | Volume: 280 | Issue: 1 | Pages: 56-65

10.1097/sla.0000000000006248 | PMID 38407228 Get It

Objective: The REDISCOVER consensus conference aimed at developing and validating guidelines on the perioperative care of patients with borderline-resectable (BR-) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC). Background: Coupled with improvements in chemotherapy and radiation, the contemporary approach to pancreatic surgery supports the resection of BR-PDAC and, to a lesser extent, LA-PDAC. Guidelines outlining the selection and perioperative care for these patients are lacking. Methods: The Scottish Intercollegiate Guidelines Network (SIGN) methodology was used to develop the REDISCOVER guidelines and create recommendations. The Delphi approach was used to reach a consensus (agreement ≥80%) among experts. Recommendations were approved after a debate and vote among international experts in pancreatic surgery and pancreatic cancer management. A Validation Committee used the AGREE II-GRS tool to assess the methodological quality of the guidelines. Moreover, an independent multidisciplinary advisory group revised the statements to ensure adherence to nonsurgical guidelines. Results: Overall, 34 recommendations were created targeting centralization, training, staging, patient selection for surgery, possibility of surgery in uncommon scenarios, timing of surgery, avoidance of vascular reconstruction, details of vascular resection/reconstruction, arterial divestment, frozen section histology of perivascular tissue, extent of lymphadenectomy, anticoagulation prophylaxis, and role of minimally invasive surgery. The level of evidence was however low for 29 of 34 clinical questions. Participants agreed that the most conducive means to promptly advance our understanding in this field is to establish an international registry addressing this patient population (https://rediscover.unipi.it/). Conclusions: The REDISCOVER guidelines provide clinical recommendations pertaining to pancreatectomy with vascular resection for patients with BR-PDAC and LA-PDAC, and serve as the basis of a new international registry for this patient population.
Neuro‐immune interactions in health and disease: Insights from FENS‐Hertie 2022 Winter School
Binder, Luisa Bandeira , Rosa, Priscila B. , Sousa, Bárbara M. de , Chagas, Luana da Silva , Dubljević, Olga , Martineau, Fanny Sandrine , Mottarlini, Francesca , Castany, Sílvia , Morton, Lorena , Krstanović, Fran , Tassinari, Isadora D’Ávila , Choconta, Jeiny Luna, Pereira-Santos, A. Raquel , Pallegar, Praveen N., Vahsen, Björn F. , Compagnion, Anne‐Claire , Picón, Marina Lorente , Binder, Luisa B , de Sousa, Bárbara M , Chagas, Luana S , Weinhard, Laetitia , Lepiarz‐Raba, Izabela

Mayo Clinic

European Journal of Neuroscience | February 7, 2024 | Volume: 59 | Issue: 8 | Pages: 1977-1992

10.1111/ejn.16262 | PMID 38311960 Get It

Abstract In a great partnership, the Federation of European Neuroscience Societies (FENS) and the Hertie Foundation organized the FENS‐Hertie 2022 Winter School on ‘Neuro‐immune interactions in health and disease’. The school selected 27 PhD students and 13 postdoctoral fellows from 20 countries and involved 14 faculty members experts in the field. The Winter School focused on a rising field of research, the interactions between the nervous and both innate and adaptive immune systems under pathological and physiological conditions. A fine‐tuned neuro‐immune crosstalk is fundamental for healthy development, while disrupted neuro‐immune communication might play a role in neurodegeneration, neuroinflammation and aging. However, much is yet to be understood about the underlying mechanisms of these neuro‐immune interactions in the healthy brain and under pathological scenarios. In addition to new findings in this emerging field, novel methodologies and animal models were presented to foment research on neuro‐immunology. The FENS‐Hertie 2022 Winter School provided an insightful knowledge exchange between students and faculty focusing on the latest discoveries in the biology of neuro‐immune interactions while fostering great academic and professional opportunities for early‐career neuroscientists from around the world.
Awake Craniotomy Program Implementation
Bojaxhi, Elird , Dholakia, Ruchita, Kim, Han, Sousa‐Pinto, Bernardo , Mendhi, Marvesh , Sherman, Wendy, Christel, Lynda, Rosenfeld, Steven S. , Middlebrooks, Erik H. , Sabsevitz, David S. , Gruenbaum, Benjamin F. , Chaichana, Kaisorn L. , Quiñones‐Hinojosa, Alfredo , Moniz-Garcia, Diogo, Rosenfeld, Steven, Middlebrooks, Erik H , Gruenbaum, Benjamin Fredrick , Moniz‐Garcia, Diogo , Borah, Bijan J. , Almeida, João Paulo , Freeman, William D. , Grewal, Sanjeet S.

Mayo Clinic

JAMA Network Open | January 24, 2024 | Volume: 7 | Issue: 1 | Pages: e2352917

10.1001/jamanetworkopen.2023.52917 | PMID 38265799 Get It

ImportanceImplementing multidisciplinary teams for treatment of complex brain tumors needing awake craniotomies is associated with significant costs. To date, there is a paucity of analysis on the cost utility of introducing advanced multidisciplinary standardized teams to enable awake craniotomies.ObjectiveTo assess the cost utility of introducing a standardized program of awake craniotomies.Design, Setting, and ParticipantsA retrospective economic evaluation was conducted at Mayo Clinic Florida. All patients with single, unilateral lesions who underwent elective awake craniotomies between January 2016 and December 2021 were considered eligible for inclusion. The economic perspective of the health care institution and a time horizon of 1 year were considered. Data were analyzed from October 2022 to May 2023.ExposureTreatment with an awake craniotomy before standardization (2016-2018) compared with treatment with awake craniotomy after standardization (2018-2021).Main Outcomes and MeasuresPatient demographics, perioperative, and postoperative outcomes, including length of stay, intensive care (ICU) admission, extent of resection, readmission rates, and 1-year mortality were compared between patients undergoing surgery before and after standardization. Direct medical costs were estimated from Medicare reimbursement rates for all billed procedures. A cost-utility analysis was performed considering differences in direct medical costs and in 1-year mortality within the periods before and after standardization of procedures. Uncertainty was explored in probability sensitivity analysis.ResultsA total of 164 patients (mean [SD] age, 49.9 [15.7] years; 98 [60%] male patients) were included in the study. Of those, 56 underwent surgery before and 108 after implementation of procedure standardization. Procedure standardization was associated with reductions in length of stay from a mean (SD) of 3.34 (1.79) to 2.46 (1.61) days (difference, 0.88 days; 95% CI, 0.33-1.42 days; P = .002), length of stay in ICU from a mean (SD) of 1.32 (0.69) to 0.99 (0.90) nights (difference, 0.33 nights; 95% CI, 0.06-0.60 nights; P = .02), 30-day readmission rate from 14% (8 patients) in the prestandardization cohort to 5% (5 patients) (difference, 9%; 95% CI, 19.6%-0.3%; P = .03), while extent of resection and intraoperative complication rates were similar between both cohorts. The standardized protocol was associated with mean (SD) savings of $7088.80 ($12 389.50) and decreases in 1-year mortality (dominant intervention). This protocol was found to be cost saving in 75.5% of all simulations in probability sensitivity analysis.Conclusions and RelevanceIn this economic evaluation of standardization of awake craniotomy, there was a generalized reduction in length of stay, ICU admission time, and direct medical costs with implementation of an optimized protocol. This was achieved without compromising patient outcomes and with similar extent of resection, complication rates, and reduced readmission rates.
Frailty as a Predictor of Postoperative Morbidity and Mortality in Patients Aged 80 Years and Older Undergoing Instrumented Fusion
Moniz‐Garcia, Diogo , Odeh, Nour , Genel, Oktay , Sousa‐Pinto, Bernardo , Otamendi-Lopez, Andrea, Nottmeier, Eric W. , Bydon, Mohamad , McClendon, Jamal, Buchanan, Ian A. , Pirris, Stephen M. , Chen, Selby , Montaser, Alaa, Nottmeier, Eric, Pirris, Stephen , Garcia, Diogo Moniz , Montaser, Alaa S. , Biase, Gaetano De , Abode-Iyamah, Kingsley

Mayo Clinic

Operative Neurosurgery | January 8, 2024 | Volume: 26 | Issue: 6 | Pages: 669-676

10.1227/ons.0000000000001040 | PMID 38189376 Get It

BACKGROUND AND OBJECTIVES: Degenerative spine disease is a leading cause of disability, with increasing prevalence in the older patients. While age has been identified as an independent predictor of outcomes, its predictive value is limited for similar older patients. Here, we aimed to determine the most predictive frailty score of adverse events in patients aged 80 and older undergoing instrumented lumbar fusion. METHODS: We proceeded with a multisite (3 tertiary academic centers) retrospective review including patients undergoing instrumented fusion aged 80 and older from January 2010 to present. A composite end point encompassing 30-day return to operating room, readmission, and mortality was created. We estimated the area under the receiver operating characteristic curve for frailty scores (Modified Frailty Index-5 [MFI-5], Modified Frailty Index-11 [MFI-11], and Charlson Comorbidity Index [CCI]) in relation to that composite score. In addition, we estimated the association between each score and the composite end point by means of logistic regression. RESULTS: A total of 153 patients with an average age of 85 years at the time of surgery were included. We observed a 30-day readmission rate of 11.1%, reoperation of 3.9%, and mortality of 0.6%. The overall rate of the composite end point at 30 days was 25 (15.1%). The AUC for MFI-5 was 0.597 (0.501-0.693), for MFI-11 was 0.620 (0.518-0.723), and for CCI was 0.564 (0.453-0.675). The association between the scores and composite end point did not reach statistical significance for MFI-5 (odds ratio [OR] = 1.45 [0.98-2.15], P = .061) and CCI (OR = 1.13 [0.97-1.31], P = .113) but was statistically significant for MFI-11 (OR = 1.46 [1.07-2.00], P = .018). CONCLUSION: This is the largest study comparing frailty index scores in octogenarians undergoing instrumented lumbar fusion. Our findings suggest that while MFI-11 score correlated with adverse events, the predictive ability of existing scores remains limited, highlighting the need for better approaches to identify select patients at age extremes.
Novel Benchmark Values for Open Major Anatomic Liver Resection in Non-cirrhotic Patients
Silva, Richard X. Sousa Da , Breuer, Eva , Shankar, Sadhana , Hołówko, Wacław , Coelho, João Santos, Jeddou, Heithem , Sugiura, Teiichi , Ghallab, Mohammed, Silva, Doris Da, Watanabe, Genki , Sakai, Nozomu , Addeo, Pietro , Tzedakis, Stylianos , Bartsch, F. , Balcer, Kaja, Lim, Chétana , Werey, Fabien, López, Víctor , Montero, Luciana Peralta, Clariá, Rodrigo Sanchez, Leiting, Jennifer L. , Vachharajani, Neeta , Hopping, Eve , Andel, Daan, Hagendoorn, Jeroen , Psica, Alicja , Ahn, Keun Soo , Montes, Leonardo A., Gunasekaran, Ganesh , Alcázar, C. , Lim, Jin Hong , Haroon, Muhammad, Lü, Qian , Castaldi, Antonio , Orimo, Tatsuya , Abadía, Teresa, Hasan, Josefina Dib, Kaufmann, Emmanuele F., Wilde, Roeland F. de , Boggi, Ugo , Hernandez‐Alejandro, Roberto, Serrablo, Alejandro , Taketomi, Akinobu , Dong, Jiahong , Hanif, Faisal, Park, Joon Seong , Schwartz, Myron , Ramisch, Diego , Oliveira, Michelle de , Oldhafer, K.J., Kang, Koo Jeong , Lodge, P., Rinkes, Inne H. M. Borel, Thomson, John‐Edwin , Goh, Su Kah , Chapman, William C. , Pekolj, Juan , Scatton, Olivier , Truant, Stéphanie , Lang, Hauke , Bachellier, Philippe , Otsuka, Masayuki, Popescu, Irinel , Cherqui, Daniel , Uesaka, Katsuhiko , Marques, Hugo P. , Grąt, Michał , Petrowsky, Henrik , Ebata, Tomoki , Prachalias, Andreas , Clavien, Pierre‐Alain , Kauffmann, Emanuele F. , Leiting, Jennifer, Chapman, William C , Shankar, Sadhana , Kawakatsu, Shoji , Botea, Florin , Torres, Orlando Jorge Martins , Hirano, Satoshi , Ravaioli, Matteo , Reese, Tim , Montes, Leonardo A., Castaldi, Antonio, Moeckli, Beat , Ruffolo, Luis I. , Hasan, Josefina Dib, Ratti, Francesca , Polak, Wojciech G. , Aldrighetti, Luca , McCormack, Lucas , Toso, Christian , Gugenheim, Jean , Ramia, José Manuel , Cescon, Matteo , Rinkes, Inne H.M. Borel , Noji, Takehiro , Cleary, Sean P. , Regimbeau, Jean‐Marc , Fuks, David , Hasegawa, Kiyoshi , Lesurtel, Mickaël , Adam, René , Boudjéma, Karim , Robles, R

Mayo Clinic

Annals of Surgery | July 19, 2023 | Volume: 278 | Issue: 5 | Pages: 748-755

10.1097/sla.0000000000006012 | PMID 37465950 Get It

Objective: This study aims at establishing benchmark values for best achievable outcomes following open major anatomic hepatectomy for liver tumors of all dignities. Background: Outcomes after open major hepatectomies vary widely lacking reference values for comparisons among centers, indications, types of resections, and minimally invasive procedures. Methods: A standard benchmark methodology was used covering consecutive patients, who underwent open major anatomic hepatectomy from 44 high-volume liver centers from 5 continents over a 5-year period (2016–2020). Benchmark cases were low-risk non-cirrhotic patients without significant comorbidities treated in high-volume centers (≥30 major liver resections/year). Benchmark values were set at the 75th percentile of median values of all centers. Minimum follow-up period was 1 year in each patient. Results: Of 8044 patients, 2908 (36%) qualified as benchmark (low-risk) cases. Benchmark cutoffs for all indications include R0 resection ≥78%; liver failure (grade B/C) ≤10%; bile leak (grade B/C) ≤18%; complications ≥grade 3 and CCI ® ≤46% and ≤9 at 3 months, respectively. Benchmark values differed significantly between malignant and benign conditions so that reference values must be adjusted accordingly. Extended right hepatectomy (H1, 4-8 or H4-8) disclosed a higher cutoff for liver failure, while extended left (H1-5,8 or H2-5,8) were associated with higher cutoffs for bile leaks, but had superior oncologic outcomes, when compared to formal left hepatectomy (H1-4 or H2-4). The minimal follow-up for a conclusive outcome evaluation following open anatomic major resection must be 3 months. Conclusion: These new benchmark cutoffs for open major hepatectomy provide a powerful tool to convincingly evaluate other approaches including parenchymal-sparing procedures, laparoscopic/robotic approaches, and alternative treatments, such as ablation therapy, irradiation, or novel chemotherapy regimens.
#5128 PREDICTIVE FACTORS OF RENAL RECOVERY AND END-STAGE KIDNEY DISEASE IN PATIENTS WITH SEVERE ANCA-ASSOCIATED VASCULITIS WITH GLOMERULONEPHRITIS
Patricio, Marc, Romeo, María José Soler, Román, Juan León , Sousa, Círia, Zand, Ladan , Sethi, Sanjeev , Moura, Marta Casal , Zubidat, Dalia , Patricio, Marc, Santos, Fernanda dos , Nardelli, Luca , Román, Juan Carlos León , Warrington, Kenneth J. , Specks, Ulrich , Fervenza, Fernando C.

Mayo Clinic

Nephrology Dialysis Transplantation | June 14, 2023 | Volume: 38 | Issue: Supplement_1 | Pages: No page available

10.1093/ndt/gfad063c_5128 Get It

Abstract Background and Aims A significant number of patients with anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) with glomerulonephritis (AAV-GN) still progress to end-stage kidney disease (ESKD, eGFR<15mL/min/1.73m2) despite advances in remission-induction treatment. Method A retrospective cohort study on MPO- or PR3-ANCA positive patients with AAV (MPA or GPA) and ESKD at presentation. Renal recovery, dialysis discontinuation and maintenance in ESKD after standard remission-induction, with or without the use of PLEX were compared. Results We analyzed 166 patients with biopsy proven active kidney involvement and eGFR <15mL/min/1.73m2 at the time of AAV-GN diagnosis. Patients received glucocorticoids with CYC (n = 84) or with RTX (n = 72) for remission-induction, and 49 also received PLEX. The predictors for renal recovery were erythrocyte sedimentation rate, SCr at diagnosis and minimal or mild chronicity changes. We analyzed 71 patients who started dialysis with or without PLEX within 4 weeks from AAV-GN diagnosis. The predictors for dialysis discontinuation were minimal chronicity changes in kidney biopsy at the time of diagnosis (OR 6.138, [95%CI 1.389-27.118],p = 0.017) and focal glomerular involvement (OR 5.017,[95%CI 1.287-19.567],p = 0.020). Predictors for maintenance in ESKD at 12 months included higher serum creatinine (SCr) at the time of diagnosis (IRR 1.086, [95%CI 1.005-1.173],p = 0.037), moderate (IRR 3.797,[95%CI 1.090-13.225],p = 0.036), or severe chronicity changes in kidney biopsy (IRR 5.883,[95%CI 1.542–22.439],p = 0.009). Conclusion In our cohort, kidney recovery, dialysis discontinuation, and maintenance of ESKD in patients with AAV-GN and eGFR<15mL/min/1.73m2 depended on SCr and histologic findings on kidney biopsies at the time of diagnosis and was not affected by the addition of PLEX.
Thyroid Disease, Hypertension, and Pregnancy: The Need for Balance Illustrated in 2 Cases
Sousa, Círia, Kattah, Andrea G. , Stan, Marius, Kattah, Andrea, Garovic, Vesna D. , Stan, Marius N. , Fervenza, Fernando C.

Mayo Clinic

American Journal of Hypertension | March 30, 2023 | Volume: 36 | Issue: 7 | Pages: 411-414

10.1093/ajh/hpad030 | PMID 36996311 Get It

Abstract Thyroid dysfunction in pregnancy has been associated with hypertensive disorders of pregnancy and poor maternal and fetal outcomes. In this article, we describe two cases of significant thyroid dysfunction leading to new diagnoses of chronic hypertension in pregnancy and review physiologic changes in the thyroid gland, placenta and maternal cardiovascular system during pregnancy.
Abstract PD18-01: Adjuvant Trastuzumab Emtansine Versus Paclitaxel plus Trastuzumab for Stage I HER2+ Breast Cancer: 5-year results and correlative analyses from ATEMPT (TBCRC033)
Tayob, Nabihah , Dang, Chau T. , Isakoff, Steven J. , Valero, Vicente , Faggen, Meredith, Mulvey, Therese M. , Bose, Ron , Weckstein, Douglas, Reeder‐Hayes, Katherine E. , Rugo, Hope, Ramaswamy, Bhuvaneswari , Zuckerman, Dan Sayam , Hart, Lowell L., Gadi, Vijayakrishna K. , Constantine, Michael, Cheng, Kit , Garrett, Audrey Merrill, Albain, Kathy S. , DeFusco, Patricia, Tung, Nadine, Ardman, Blair, Nanda, Rita , Jankowitz, Rachel C. , Rimawi, Mothaffar F. , Pohlmann, Paula R. , Poznak, Catherine Van , Forero-Torres, Andres , Liu, Minetta C. , Ruddy, Kathryn, Waks, Adrienne G. , DeMeo, Michelle K. , Burstein, Harold J. , Partridge, Ann, Viale, Giuseppe , Hui, Winnie W. , Schneider, Bryan P. , Krop, Ian E. , Tolaney, Sara M. , Rimawi, Mothaffar , Pohlmann, Paula , Tarantino, Paolo , Yardley, Denise Aysel , Wolff, Antonio C. , Marcom, Paul Kelly , Tung, Nadine , Abramson, Vandana G. , Ruddy, Kathryn J. , Zheng, Yue , Barroso‐Sousa, Romualdo , DiLullo, Molly K. , Curigliano, Giuseppe , Winer, Eric P. , Mittendorf, EA , Prat, Aleix

Mayo Clinic

Cancer Research | March 2, 2023 | Volume: 83 | Issue: 5_Supplement | Pages: PD18-01-PD18-01

10.1158/1538-7445.sabcs22-pd18-01 Get It

Abstract Background: The ATEMPT trial primary analysis found that one year of adjuvant trastuzumab emtansine (T-DM1) achieved a 3-year iDFS of 97.8% for patients with stage I HER2+ breast cancer, but was not associated with fewer clinically relevant toxicities (CRTs) compared with paclitaxel and trastuzumab (TH). In this end-of-study analysis, we report 5-year survival outcomes and correlative analyses from the trial. Methods: Patients with stage I centrally confirmed HER2+ breast cancer were randomly assigned 3:1 to adjuvant T-DM1 for one year or TH and received T-DM1 3.6 mg/kg IV every 3 weeks for 17 cycles or paclitaxel 80 mg/m2 IV with weekly trastuzumab IV followed by trastuzumab for 9 months. The co-primary objectives were to compare the incidence of CRTs between the 2 arms and to evaluate iDFS in patients receiving T-DM1. To investigate proteomic correlates of recurrence, spatial proteomic analyses were performed on samples from 13 patients experiencing iDFS events (cases) and 24 matched controls using the NanoString GeoMx Digital Spatial Profiler. The impact of HER2 heterogeneity on outcomes was investigated among 17 cases and 51 matched controls by fluorescence in-situ hybridization (FISH). HER2 genetic heterogeneity was assessed by scrutinizing the whole tumor area and defined as the occurrence of HER2 gene amplification in >5% but < 50% invasive tumor cells. The risk of recurrence was evaluated centrally with the HER2DX genomic assay from 225 primary tumor samples. Germline whole genome sequencing (WGS) was conducted among 55 patients experiencing T-DM1-induced thrombocytopenia and/or bleeding and 55 matched controls to identify genomic correlates for this side effect. Results: A total of 497 patients who initiated protocol therapy were included in this analysis (383 T-DM1 and 114 TH). After a median follow up 5.8 years, among patients receiving T-DM1 there were a total of 11 iDFS events, with 3 distant recurrences. The 5-year iDFS for T-DM1 was 97.0% (95% CI, 95.3-98.8%), the 5-year recurrence-free interval (RFI) was 98.6% (95% CI: 97.4-99.8%) and the 5-year overall survival (OS) for T-DM1 was 97.8 % (95% CI, 96.3-99.3%). Although the study was not powered to evaluate the efficacy of TH, among the 114 patients receiving TH, a total of 9 iDFS events were observed, including 2 distant events; the 5-year iDFS with TH was 91.3% (95% CI: 86.0-96.9%), 5-year RFI was 93.3% (95% CI: 88.6-98.2%) and 5-year OS was 97.9% (95% CI: 95.2-100%). A total of 56 samples were evaluable for heterogeneity analyses, among which 14% (n=8) harbored HER2 genetic heterogeneity. Spatial proteomic analyses found that NF1 (adjusted p=0.72 × 10-6) and CTLA-4 (adjusted p=0.15 × 10-3) were significantly upregulated in primary samples from cases, while cleaved caspase 9, CD25, GITR, ICOS, p53 and PD-L2 were significantly upregulated in controls (all with adjusted p< 0.05). Germline WGS found that the top gene associations with thrombocytopenia and thrombocytopenia or bleeding were ALMS1 (p=0,19 × 10-3) and APBA3 (p=0,23 × 10-3), respectively, although none reaching the threshold for genome wide significance. rs62143195 and rs114169776 were the top single nucleotide polymorphisms associated with thrombocytopenia and thrombocytopenia or bleeding, respectively. Data on the impact of HER2 heterogeneity and of HER2DX score on survival outcomes will be presented. Conclusion: With longer follow-up, adjuvant T-DM1 confirmed outstanding long-term outcomes among patients with stage I HER2+ breast cancer, demonstrating a 5-year RFI of 98.6%. Spatial proteomic analyses identified a potential association between NF1 and CTLA-4 expression with recurrence. Details on the impact of HER2 heterogeneity and HER2DX assay on prognosis will be presented. Citation Format: Paolo Tarantino, Nabihah Tayob, Chau T Dang, Denise Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Douglas Weckstein, Antonio C. Wolff, Katherine Reeder-Hayes, Hope Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K. Gadi, Michael Constantine, Kit Cheng, Audrey Merrill Garrett, Paul K. Marcom, Kathy S. Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel C. Jankowitz, Mothaffar Rimawi, Vandana Abramson, Paula R. Pohlmann, Catherine Van Poznak, Andres Forero-Torres, Minetta C. Liu, Kathryn Ruddy, Yue Zheng, Romualdo Barroso-Sousa, Adrienne Waks, Michelle K. DeMeo, Molly K. DiLullo, Giuseppe Curigliano, Harold Burstein, Ann Partridge, Eric Winer, Giuseppe Viale, Winnie Hui, Elizabeth A. Mittendorf, Bryan P. Schneider, Aleix Prat, Ian Krop, Sara Tolaney. Adjuvant Trastuzumab Emtansine Versus Paclitaxel plus Trastuzumab for Stage I HER2+ Breast Cancer: 5-year results and correlative analyses from ATEMPT (TBCRC033) [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr PD18-01.
A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF/FGFR alterations.
Ciombor, Kristen K. , Jia, Jingquan, Gbolahan, Olumide B., Waechter, Blake, Zemla, Tyler , Hubbard, Joleen M. , Sousa, Andrea, Wilson, Luke, Ou, Fang‐Shu , Nixon, Andrew B. , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | January 24, 2023 | Volume: 41 | Issue: 4_suppl | Pages: 139-139

10.1200/jco.2023.41.4_suppl.139 Get It

139 Background: The fibroblast growth factor receptor (FGFR) pathway plays a key role in cellular proliferation, migration, survival and angiogenesis. Aberrant signaling through FGFR in colorectal cancer and other malignancies results from gene amplification or mutation, chromosomal translocation or ligand-dependent activation of the receptors. Pemigatinib is an oral inhibitor of FGFR1-3 with proven efficacy in FGFR-altered cholangiocarcinoma and myeloid/lymphoid neoplasms, among others. We hypothesized that pemigatinib would improve response rates compared to historical controls in patients with refractory FGF/FGFR-altered mCRC. Methods: ACCRU-GI-1701 was a multicenter, single-arm, Simon’s two-stage phase II clinical trial (NCT04096417) of the FGFR inhibitor pemigatinib in patients (pts) with FGF/FGFR-altered mCRC. Eligible pts had received prior fluoropyrimidine, oxaliplatin, irinotecan, and anti-VEGF/anti-EGFR/anti-PD-1 if eligible. Pts received pemigatinib 13.5 mg once daily on d1-21 of each cycle, with option to escalate to 18 mg in c2 if well tolerated. The primary endpoint was (unconfirmed) objective response (OR). A sample size of 21 evaluable pts would provide 82% power to detect a true OR rate of 20% or greater compared to a historical control of 5 % with a one-sided type I error rate of 0.1. A prespecified interim analysis for futility was planned after 12 evaluable patients. Results: A total of 14 patients were enrolled in the first stage of the study, and all were evaluable for the primary endpoint. No OR were observed (out of 12) crossing the futility boundary and resulting in permanent closure of the study. Among all enrolled patients, median age was 60.5 years, 71.4% were male, 92.9% Caucasian, 42.9% with no prior exposure to TAS-102 or regorafenib, and 64.3% with left-sided primary tumors. Treated patients all had tumors with FGFR1-4 mutations and/or FGF/FGFR amplifications by tissue- and/or blood-based molecular testing; no FGFR translocations were present. OR rate for this study was 0% (95% CI, 0-23.2%), with one patient achieving stable disease as best response. Median progression-free survival was 9.1 weeks (95% CI, 7.9-not evaluable [NE]), and median overall survival was 7.9 months (95% CI, 3.4-NE). Grade 3+ adverse events (AE) were seen in 42.9% of treated patients (including 1 grade 5 AE). Most commonly occurring AEs of any grade were anemia, hyperphosphatemia, alkaline phosphatase increased, aspartate aminotransferase increase, and fatigue. Conclusions: Pemigatinib demonstrated evidence of safety but not clinical activity in this population of patients with FGF/FGFR-altered mCRC. It is unknown whether pemigatinib would be active in mCRC patients with FGFR translocations/fusions as these were not represented in our trial. Translational studies are planned to investigate mechanisms of resistance to this therapy. Clinical trial information: NCT04096417 .
Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort
Vollstedt, Eva‐Juliane , Schaake, Susen , Lohmann, Katja , Lesage, Suzanne , Tesson, Christelle , Wurster, Isabel , Hentati, F., Marder, Karen, Waters, Cheryl , Fahn, Stanley, Brüggemann, Norbert , Tolosa, Eduardo , Garrido, Alícia , Annesi, Grazia , Bozi, Maria , Ferreira, Joaquim J. , Guedes, Leonor Correia , Petrucci, Simona , Clark, Lorraine N. , Abramycheva, Natalya, Menéndez‐González, Manuel , Maestre, S. Jesús, Gómez‐Garre, Pilar , Mir, Pablo , Ran, Caroline , Kuo, Ming‐Che , Ross, Owen A. , Williams‐Gray, Caroline H. , Camacho, Marta , Cornejo‐Olivas, Mario , Torres-Ramírez, Luis , Wu, Yih‐Ru , Morgadinho, Ana , Berg, Daniela , Kuhlenbäumer, Gregor , Kühn, Andrea A. , Borngräber, Friederike , Michele, Giuseppe De , Rosa, Anna De , Zimprich, Alexander , Puschmann, Andreas , Mellick, George D. , Chase, Bruce A. , Markopoulou, Katerina , Satake, Wataru , Rossi, Malco , Lynch, Timothy , Olszewska, Diana A. , Lim, Shen‐Yang , Ahmad‐Annuar, Azlina , Tan, Ai Huey , Hanağası, Haşmet , Koziorowski, Dariusz , Ertan, Sibel , Genç, Gençer , Saunders‐Pullman, Rachel , Warrenburg, Bart van de, Bressman, Susan , Toft, Mathias , Appel‐Cresswell, Silke , Boon, Agnita J.W. , Krüger, Rejko , Sammler, Esther , Tumas, Vítor , Zhang, Baorong , Garraux, Gaëtan , Kim, Yun Joong , Winkelmann, Juliane , Sue, Carolyn M. , Tan, Eng‐King , Kostić, Vladimir , Arkadir, David , Martikainen, Mika H. , Brighina, Laura , Suchowersky, Oksana , Rieß, Olaf , Das, Parimal, Mollenhauer, Brit , Gatto, Emilia , Petersen, Maria Skaalum , Aasly, Jan , Aasly, Anna, Farrer, Matthew J. , Brockmann, Kathrin , Klein, Christine , Group, the MJFF Global Genetic Parkinson's Disease Study, Bardien, Soraya , Barrett, Matthew J. , Januário, Cristina , Sousa, Mário , Soto‐Beasley, Alexandra I. , May, Patrick , Mirelman, Anat , Brüggemann, Norbert , Borsche, Max , Tolosa, Eduardo , Ferreira, Joaquim J , Alvarez, Victoria , Mir, Pablo , Kuo, Ming-Che , Ross, Owen A , Nishioka, Kenya , Williams-Gray, Caroline H , Camacho, Marta , Cornejo-Olivas, Mario , Wu, Yih-Ru , Termsarasab, Pichet , Borngräber, Friederike , Zimprich, Alexander , Gambardella, Stefano , Chase, Bruce , Olszewska, Diana A , Tan, Ai Huey , Barkhuizen, Melinda , Appel-Cresswell, Silke , Skorvanek, Matej , Sammler, Esther M , Zhang, Baorong , Chung, Sun Ju , Puschmann, Andreas , Januário, Cristina , Klein, Christine , Bardien, Soraya , Toft, Mathias , Koziorowski, Dariusz , May, Patrick , Beasley, Alexandra I , Barrett, Matthew J , Sue, Carolyn M , Kühn, Andrea A , Padmanabhan, Shalini , Brice, Alexis , Vidailhet, Marie , Giladi, Nir , Kasten, Meike , Borsche, Max , Foroud, Tatiana , Gagliardi, Monica , Stefanis, Leonidas , Avenali, Micol , Fedotova, E. Yu. , Álvarez, Victoria , Belin, Andrea Carmine , Lin, Chin‐Hsien , Crosiers, David , Wszołek, Zbigniew K. , Jankovic, Joseph J. , Funayama, Manabu , Clarimón, Jordi , Lee‐Chen, Guey‐Jen , Pulkes, Teeratorn , Dorszewska, Jolanta , Carr, Jonathan , Ferese, Rosangela , Toda, Tatsushi , Merello, Marcelo , Al-Mubarak, Bashayer R , Aguiar, Patrícia de Carvalho , Pimentel, Márcia Mattos Gonçalves , Warrenburg, Bart P.C. van de , Lang, Anthony E. , Damásio, Joana , Klivènyi, Péter , Borges, Vanderci , Hertz, Jens Michael , Spitz, Mariana , Hattori, Nobutaka , Wu, Ruey‐Meei , Illarioshkin, Sergey Nikolaevich , Valente, Enza Maria , Alcalay, Roy N. , Thaler, Avner , Corvol, Jean‐Christophe , Group, the MJFF Global Genetic Parkinson's Disease Study

Mayo Clinic

Movement Disorders | January 24, 2023 | Volume: 38 | Issue: 2 | Pages: 286-303

10.1002/mds.29288 | PMID 36692014 Get It

AbstractBackgroundAs gene‐targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction of the estimated number of subjects with monogenic PD worldwide are currently represented in the literature and availability of clinical data and clinical trial‐ready cohorts is limited.ObjectiveThe objectives are to (1) establish an international cohort of affected and unaffected individuals with PD‐linked variants; (2) provide harmonized and quality‐controlled clinical characterization data for each included individual; and (3) further promote collaboration of researchers in the field of monogenic PD.MethodsWe conducted a worldwide, systematic online survey to collect individual‐level data on individuals with PD‐linked variants in SNCA, LRRK2, VPS35, PRKN, PINK1, DJ‐1, as well as selected pathogenic and risk variants in GBA and corresponding demographic, clinical, and genetic data. All registered cases underwent thorough quality checks, and pathogenicity scoring of the variants and genotype–phenotype relationships were analyzed.ResultsWe collected 3888 variant carriers for our analyses, reported by 92 centers (42 countries) worldwide. Of the included individuals, 3185 had a diagnosis of PD (ie, 1306 LRRK2, 115 SNCA, 23 VPS35, 429 PRKN, 75 PINK1, 13 DJ‐1, and 1224 GBA) and 703 were unaffected (ie, 328 LRRK2, 32 SNCA, 3 VPS35, 1 PRKN, 1 PINK1, and 338 GBA). In total, we identified 269 different pathogenic variants; 1322 individuals in our cohort (34%) were indicated as not previously published.ConclusionsWithin the MJFF Global Genetic PD Study Group, we (1) established the largest international cohort of affected and unaffected individuals carrying PD‐linked variants; (2) provide harmonized and quality‐controlled clinical and genetic data for each included individual; (3) promote collaboration in the field of genetic PD with a view toward clinical and genetic stratification of patients for gene‐targeted clinical trials. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.